Advancing precision oncology through systematic germline and tumor genetic analysis: The oncogenetic point of view on findings from a prospective multicenter clinical trial of 666 patients.
Fiche publication
Date publication
septembre 2023
Journal
Cancer medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BINQUET Christine, Dr BOIDOT Romain, Pr GHIRINGHELLI François, Dr LANCON Allan, Pr FAIVRE Laurence, Dr FAVIER Laure, Dr NAMBOT Sophie, Dr DERANGERE Valentin
Tous les auteurs :
Mazel B, Bertolone G, Baurand A, Cosset E, Sawka C, Robert M, Gautier E, Lançon A, Réda M, Favier L, Dérangère V, Richard C, Binquet C, Boidot R, Goussot V, Albuisson J, Ghiringhelli F, Faivre L, Nambot S
Lien Pubmed
Résumé
With the emergence of targeted therapies, there is a need to accurately identify more tumor biomarkers. The EXOMA trial was designed to offer tumor and germline exome sequencing (ES) to patients with solid malignant tumors and facing therapeutic failure. As hereditary cancer predispositions could be identified, with genetic counseling and health management implications, a genetic consultation was systematically established. This design needs to be discussed as genetic human resources are limited and indication of theranostic tests will increase.
Mots clés
genetic counseling, incidental findings, information, oncogenetic, theranostic exome sequencing
Référence
Cancer Med. 2023 09 11;: